Merus N.V. - Common Shares (MRUS)

Top mid-cap stocks gained up to 53.47% in the last week, including QBTS, RGC, AAP, MRUS, OKLO, SBSW, and BGM. Are they in your portfolio?

Merus N.V. (NASDAQ: MRUS) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab for head and neck cancer.

Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.

BofA’s new price target of $92 implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.

Merus announced a research collaboration and license agreement with Biohaven.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.

The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge.

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for petosemtamab in combination with pembrolizumab.

FDA approves Merus' Bizengri as the first treatment for advanced NRG1 fusion-positive cancers. U.S. peak sales are estimated at $16.5 million.

Jim Cramer called Allison Transmission a "storied company... terrific. It does great."

Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key focus for analysts.

MRUS stock results show that Merus missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Merus announces interim clinical data on petosemtamab and Keytruda (pembrolizumab) for first-line recurrent/metastatic head and neck squamous cell carcinoma. Early results show promising efficacy with a 60% response rate.

The company passed investors' bar for success in a study of a head-and-neck cancer treatment.